Quick Summary
- EU Approval: European Commission approves higher-dose Wegovy 7.2 mg (semaglutide injection) for adults with obesity across all 27 EU member states.
- Clinical Results: STEP UP trial shows 21% average weight loss with Wegovy 7.2 mg vs. 2% with placebo; 1 in 3 patients lost 25%+ of body weight; 84% of weight loss from fat mass with preserved muscle.
- Treatment Flexibility: Patients can escalate directly from 2.4 mg to 7.2 mg dose after 4 weeks; single-dose 7.2 mg pen awaiting approval (could launch later in 2026).
- Safety Profile: Most common side effects are gastrointestinal (nausea, diarrhea, vomiting at 24.8%) and dysesthesia (22.9%), typically mild-to-moderate and transient
The European Commission has approved a new 7.2 mg once-weekly maintenance dose of Wegovy® (semaglutide injection) for adults living with obesity, expanding treatment options across all 27 European Union member states. The approval provides healthcare professionals with an additional tool to help patients requiring more aggressive weight loss intervention than the existing 2.4 mg maintenance dose can deliver.
The decision follows a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on December 12, 2025, and reflects the significant clinical benefits demonstrated in two pivotal studies.
Clinical Evidence Demonstrates Substantial Weight Loss
The regulatory approval is grounded in compelling data from the STEP UP trial, which enrolled 1,407 participants without type 2 diabetes, and the STEP UP T2D trial, which included 512 participants with type 2 diabetes. Both studies examined the efficacy and safety of the higher 7.2 mg dose over approximately 18 months.
Key findings in adults with obesity without diabetes taking Wegovy® 7.2 mg include
Weight Loss Results: Participants on the 7.2 mg dose achieved an average weight loss of 21 percent of their body weight when the medication was taken as prescribed, compared to approximately 2 percent for placebo recipients. One in three patients lost 25 percent or more of their baseline body weight, a threshold representing clinically significant improvement in obesity-related conditions.
Body Composition: Body composition analysis revealed that the majority ofthe weight lost, 84 percent, was derived from fat mass, with tests confirming preserved muscle function. This metabolic profile represents an important advantage, as maintaining lean muscle mass is critical for long-term metabolic health and functional capacity.
Tolerability: The most frequently reported adverse events were gastrointestinal in nature, including nausea, diarrhea, and vomiting (24.8 percent of participants) and dysesthesia, a sensation disorder (22.9 percent). These side effects were predominantly mild to moderate in severity and typically transient, resolving without discontinuation of therapy.
Read More: Wegovy® Shows Superior Cardiovascular Protection Over Tirzepatide in Real-World Study
Enhanced Treatment Flexibility for EU Physicians
Under the new approval, adults with obesity can progress directly from the 2.4 mg maintenance dose after a minimum of four weeks at that level to the 7.2 mg dose if greater weight loss is clinically indicated. Currently, the 7.2 mg dose will be administered as three separate 2.4 mg injections taken in a single weekly sitting, maintaining the once-weekly dosing schedule.
Novo Nordisk has submitted an application to the European Commission seeking approval of a single-dose 7.2 mg pen device, which could become available later this year if authorized. This innovation would further streamline patient administration and may improve adherence and convenience.
This approval is another important step in helping people living with obesity reach very significant weight loss. The new dose gives healthcare professionals even more flexibility to tailor treatment and help people with obesity achieve their weight loss and health goals.
Emil Kongshøj Larsen
Read More: Novo Nordisk’s Wegovy® (Semaglutide) Receives FDA Approval for MASH Treatment
Regulatory Status and Availability
The 7.2 mg dose joins an expanding array of Wegovy® injectable formulations now available throughout the EU. The complete range of approved doses includes 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg, administered once weekly as a subcutaneous injection.
Wegovy® has already been approved and is available in the United Kingdom at the 7.2 mg dose. Regulatory applications for the higher dose are pending review by the U.S. Food and Drug Administration and several other countries. Novo Nordisk is also advancing a Wegovy® oral formulation, which has achieved approval in the United States and remains under review for authorization in the European Union.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC
Pfizer's landmark Phase 3 TALAPRO-3 trial confirms that the Talzenna Xtandi rPFS mCSPC combination markedly exceeds its pre-specified efficacy target — advancing PARP inhibition earlier […]
Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide
Quick Summary 2.0% Average A1C Reduction (primary endpoint achieved). 16.8% Body Weight Loss (36.6 lbs over 40 weeks). Improved Cardiovascular Markers (cholesterol, triglycerides, blood pressure). […]
The Broader Obesity Treatment Landscape
The approval of the higher-dose Wegovy® reflects growing recognition of obesity as a chronic metabolic disease requiring pharmaceutical intervention alongside lifestyle modifications. Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide have emerged as transformative agents in weight management, offering efficacy levels substantially exceeding older pharmacological approaches.
Treatment with Wegovy® is indicated as a complement to, rather than a replacement for, healthy eating and increased physical activity. The medication works by enhancing satiety and reducing appetite through its effects on GLP-1 receptors in the brain and gastrointestinal tract.
Last Modified:
